Clinical Trial Update: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for EYP-1901 in wet age-related macular degeneration; primary efficacy to be determined at Week 56 in a 2-year study that is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• EYP-1901

Snippet

Sponsor: EyePoint Pharmaceuticals, Inc. | Conditions: Wet Age Related Macular Degeneration, wAMD | Phase 3 | Status: ACTIVE_NOT_RECRUITING